In Segment C, contributors will acquire ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the contributors are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit products within 3 days prior to https://samuelf444tds8.eqnextwiki.com/user